Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8021536 | 0.89 | MCL1 (0.60) | ALDH1A1TBXAS1KMT2ASTAT3KDM4E | |
| SCHEMBL1520240 | 0.87 | TBXAS1 (0.64) | ALDH1A1TBXAS1KMT2ASTAT3KDM4E | |
| SCHEMBL18180209 | 0.85 | CDC25A (0.63) | ALDH1A1TBXAS1KMT2ASTAT3KDM4E | |
| SCHEMBL12874520 | 0.85 | KMT2A (0.66) | ALDH1A1TBXAS1KMT2ASTAT3KDM4E | |
| SCHEMBL9701519 | 0.83 | KMT2A (0.60) | ALDH1A1TBXAS1KMT2ASTAT3KDM4E | |
| SCHEMBL29552404 | 0.82 | ALDH1A1 (0.65) | ALDH1A1TBXAS1KMT2ASTAT3KDM4E | |
| SCHEMBL22188707 | 0.82 | ALDH1A1 (0.65) | ALDH1A1TBXAS1KMT2ASTAT3KDM4E | |
| SCHEMBL22188706 | 0.82 | ALDH1A1 (0.65) | ALDH1A1TBXAS1KMT2ASTAT3KDM4E | |
| SCHEMBL22061003 | 0.80 | ALDH1A1 (0.62) | ALDH1A1TBXAS1KMT2ASTAT3KDM4E | |
| SCHEMBL30979650 | 0.80 | ALDH1A1 (0.55) | ALDH1A1TBXAS1KMT2ASTAT3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242854-A1 | Chemical capture reagent | GE HEALTHCARE UK LIMITED (GB) | 2004-12-02 | — | — | US | claimed |
| EP-1402268-A2 | CHEMICAL CAPTURE REAGENT | Amersham Biosciences UK Limited (GB) | 2004-03-31 | — | — | EP | claimed |
| WO-2003005026-A2 | CHEMICAL CAPTURE REAGENT | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2003-01-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242854-A1 | Chemical capture reagent | SPPL2B, PRXL2A, PLG | ALDH1A1 2055/4885TBXAS1 2922/4885KMT2A 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.